Symbols

PLRX

Pliant Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PLRX

Pliant Therapeutics, Inc.

A clinical stage biopharmaceutical company that developing novel therapies for fibrosis and related diseases

Industry

Pharmaceutical

Established Date

Listing Date

06/03/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.pliantrx.com

Security Type

Common stock

Office address

331 Oyster Point Boulevard South San Francisco CA 94080

Business

Introduction

Pliant Therapeutics, Inc., incorporated under the laws of the State of Delaware in June 2015, is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapies. The company's main project is dedicated to the development of solid tumor treatments by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β). With a deep understanding of integrin biology and expertise in medicinal chemistry and translational medicine, Pliant has developed a proprietary drug discovery platform for a variety of disease areas. The Company's lead product candidate, PLN-101095, is an oral small molecule drug designed to inhibit αvβ8 and αvβ1 integrins for the treatment of solid tumors. Pliant will continue to research its drug discovery platform, which includes a proprietary integrin-binding molecular library designed to enable targeted drug delivery.

Company Financials

EPS

PLRX has released its 2025 Q4 earnings. EPS was reported at -0.38, versus the expected -0.39, beating expectations. The chart below visualizes how PLRX has performed over recent quarters, highlighting trends in earnings surprises.